Casey M. Rand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Casey M. Rand has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Debra E. Weese-Mayer
Ann & Robert H Lurie Children's Hospital of Chicago
10 shared publications - Elizabeth Berry-Kravis
Rush University Medical Center, Chicago, USA
3 shared publications - N. Torben Bech-Hansen
Department of Medical Genetics, Cumming School of Medicine, Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Canada
3 shared publications - Richard J. A. Wilson
Department of Physiology and Pharmacology, Cumming School of Medicine University of Calgary Calgary Alberta Canada
3 shared publications - Sarah F. Barclay
Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Canada
3 shared publications - William Thomas Gibson
Department of Medical Genetics, University of British Columbia, Vancouver, Canada
3 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (5) , 99
From Device Data to Trusted Decision Support: Building the Foundation for AI in Hospital Insulin Management
The adoption of artificial intelligence (AI) tools for hospital insulin management is currently limited by data fragmentation and difficult integration into clinical workflows. This commentary examines the data infrastructure requirements for safe AI deployment in clinical settings. Device-mediated and clinician-administered dosing are the two methods by which insulin is managed in hospitals. In device-mediated dosing, glucose and insulin data often remain siloed within proprietary device ecosystems outside the electronic health record (EHR). In clinician-administered dosing, relevant data elements typically exist within the EHR but are distributed across workflows in ways that limit their usefulness for decision support. The Integration of Connected Diabetes Device Data into the Electronic Health Record (iCoDE) initiative is a standard for integrating device-generated diabetes data into clinical systems, which can lay the foundation for organizing hospital data in support of the development of trustworthy AI. A staged roadmap for hospitals building towards AI-ready insulin management infrastructure is presented along with governance requirements for trustworthy deployment. The value of iCoDE is that it helps define the conditions under which such AI can become clinically meaningful, trustworthy, and scalable.
- 20 May 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (5) , 99
Open AccessFrom Device Data to Trusted Decision Support: Building the Foundation for AI in Hospital Insulin Management
The adoption of artificial intelligence (AI) tools for hospital insulin management is currently limited by data fragmentation and difficult integration into clinical workflows. This commentary examines the data infrastructure requirements for safe AI deployment in clinical settings. Device-mediated and clinician-administered dosing are the two methods by which insulin is managed in hospitals. In device-mediated dosing, glucose and insulin data often remain siloed within proprietary device ecosystems outside the electronic health record (EHR). In clinician-administered dosing, relevant data elements typically exist within the EHR but are distributed across workflows in ways that limit their usefulness for decision support. The Integration of Connected Diabetes Device Data into the Electronic Health Record (iCoDE) initiative is a standard for integrating device-generated diabetes data into clinical systems, which can lay the foundation for organizing hospital data in support of the development of trustworthy AI. A staged roadmap for hospitals building towards AI-ready insulin management infrastructure is presented along with governance requirements for trustworthy deployment. The value of iCoDE is that it helps define the conditions under which such AI can become clinically meaningful, trustworthy, and scalable.
- Open Access
- 30 January 2026
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 11, e92455
The Evolving Landscape of CGM Metrics in Type 1 Diabetes: A Narrative Literature Review (Preprint)
Background: Continuous glucose monitoring (CGM) has transformed diabetes management and research by providing high-frequency data that address many of the limitations of hemoglobin A 1c , enabling more precise clinical treatment targets and responsive trial endpoints. The richness and complexity of high-resolution time-series CGM data have spurred the development of numerous metrics for both clinical care and research applications. Beyond established metrics, there is a growing set of clinical, composite, and research-oriented measures that may support clinical decision support, intervention planning, risk stratification, and discovery-oriented research. This proliferation has created significant challenges in metric selection, interpretation, calculation, and standardization, particularly when metrics are applied across different devices, populations, software packages, and study designs. Objective: The objective is to map the current landscape of CGM metrics and address ongoing challenges in metric selection, clinical and research interpretation, and standardization. We further sought to distinguish between metrics primarily suited for routine clinical interpretation and those designed to explore more granular or multidimensional features of glycemia in research settings. Methods: We identified the literature focusing on the calculation, application, and interpretation of the following categories of CGM metrics: (1) standardized, (2) clinical, (3) emerging, and (4) composite. CGM metrics included in this study were identified from the 27 metrics included in the Diabetes Research Hub platform, additional published standardized and composite metrics, metrics used in established CGM analysis software, and emerging metrics identified during review. We narratively reviewed each metric’s definitions, calculation methods, interpretation, clinical and research utility, and strengths and limitations. In total, 102 articles were reviewed, supporting the synthesis of 36 distinct CGM-derived metrics. Results: The review identifies a fundamental divide in the CGM metric landscape. Standardized and clinical metrics, including time in range, mean glucose, coefficient of variation, and similar, prioritize simplicity and actionability. These metrics facilitate rapid decision-making in clinical settings but potentially mask granular glycemic fluctuations, event patterns, and discordance between average glucose values and variability. Emerging and composite metrics offer deeper insights into glycemic patterns, risk, and variability. However, many rely on specialized software or complex formulas, lack standardized thresholds or clear relationships to clinical outcomes, and do not have consensus methods of calculation and interpretation, limiting their adoption and hindering cross-study comparison. Conclusions: While consensus exists for core clinical metrics, the lack of standardization for complex metrics hinders research replicability and clinical translation. Bridging this gap requires moving toward consensus metric definitions, open-science frameworks, and standardized code libraries. Metric selection should be guided by intended use. Clinical metrics should be well-established, interpretable, and actionable. Research metrics should be clearly described, reproducible, and linked to meaningful outcomes. This review provides a comprehensive resource for navigating the diverse spectrum of CGM metrics, clarifying their applications and limitations to support both research and clinical investigation.
- 30 January 2026
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 11, e92455
Open AccessThe Evolving Landscape of CGM Metrics in Type 1 Diabetes: A Narrative Literature Review (Preprint)
Background: Continuous glucose monitoring (CGM) has transformed diabetes management and research by providing high-frequency data that address many of the limitations of hemoglobin A 1c , enabling more precise clinical treatment targets and responsive trial endpoints. The richness and complexity of high-resolution time-series CGM data have spurred the development of numerous metrics for both clinical care and research applications. Beyond established metrics, there is a growing set of clinical, composite, and research-oriented measures that may support clinical decision support, intervention planning, risk stratification, and discovery-oriented research. This proliferation has created significant challenges in metric selection, interpretation, calculation, and standardization, particularly when metrics are applied across different devices, populations, software packages, and study designs. Objective: The objective is to map the current landscape of CGM metrics and address ongoing challenges in metric selection, clinical and research interpretation, and standardization. We further sought to distinguish between metrics primarily suited for routine clinical interpretation and those designed to explore more granular or multidimensional features of glycemia in research settings. Methods: We identified the literature focusing on the calculation, application, and interpretation of the following categories of CGM metrics: (1) standardized, (2) clinical, (3) emerging, and (4) composite. CGM metrics included in this study were identified from the 27 metrics included in the Diabetes Research Hub platform, additional published standardized and composite metrics, metrics used in established CGM analysis software, and emerging metrics identified during review. We narratively reviewed each metric’s definitions, calculation methods, interpretation, clinical and research utility, and strengths and limitations. In total, 102 articles were reviewed, supporting the synthesis of 36 distinct CGM-derived metrics. Results: The review identifies a fundamental divide in the CGM metric landscape. Standardized and clinical metrics, including time in range, mean glucose, coefficient of variation, and similar, prioritize simplicity and actionability. These metrics facilitate rapid decision-making in clinical settings but potentially mask granular glycemic fluctuations, event patterns, and discordance between average glucose values and variability. Emerging and composite metrics offer deeper insights into glycemic patterns, risk, and variability. However, many rely on specialized software or complex formulas, lack standardized thresholds or clear relationships to clinical outcomes, and do not have consensus methods of calculation and interpretation, limiting their adoption and hindering cross-study comparison. Conclusions: While consensus exists for core clinical metrics, the lack of standardization for complex metrics hinders research replicability and clinical translation. Bridging this gap requires moving toward consensus metric definitions, open-science frameworks, and standardized code libraries. Metric selection should be guided by intended use. Clinical metrics should be well-established, interpretable, and actionable. Research metrics should be clearly described, reproducible, and linked to meaningful outcomes. This review provides a comprehensive resource for navigating the diverse spectrum of CGM metrics, clarifying their applications and limitations to support both research and clinical investigation.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Recognition of a Critical Functional Domain and Improved PHOX2B Missense Variant Interpretation by Utilization of In Silico Prediction Tools
Pathogenic heterozygous variants in PHOX2B are associated with congenital central hypoventilation syndrome (CCHS), which is characterized by autonomic nervous system dysregulation severely affecting respiratory control. The interpretation of PHOX2B missense variation is challenging due to their rarity and the lack of available functional evidence. Consequently, most PHOX2B missense variants are classified as variants of uncertain significance (VUSs), complicating the timely diagnosis and clinical management of the condition. To generate an improved model for assessments of PHOX2B missense variants, a methodology was derived to evaluate all PHOX2B missense variants in the literature and public/private databases according to a consensus classification framework and assigned pathogenicity classifications. Pathogenicity prediction scores from the in silico prediction tools CADD, REVEL, BayesDel, and AlphaMissense were obtained for all variants. A weighted logistic regression in a multiple imputation framework was performed to assess the strength of evidence supporting application of ACMG/AMP guidelines′ PP3/BP4 criteria. CADD, REVEL, and BayesDel meet the predictive strengths for PP3/BP4 recommended by the Clinical Genome Resource (ClinGen). Based on their areas under the curve and low proportions of variants with indeterminate pathogenicity predictions, BayesDel and REVEL were the strongest predictive tools and should be utilized for routine PHOX2B missense variant assessment with this study′s calculated score thresholds for PP3/BP4 strength levels. Furthermore, the positional distribution of pathogenic and benign variants was analyzed to assess potential hotspots or critical functional domains in PHOX2B , and pathogenic variants were found to cluster in the homeodomain. The enrichment of pathogenic variation was substantiated by the prediction tools, supporting the use of the PM1 criterion for variants in the homeodomain. This calibration of existing computational prediction tools for PHOX2B missense variant classification and recognition of the homeodomain variants will enable fewer VUS classifications in favor of conclusive results, aiding in these individuals′ care.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessRecognition of a Critical Functional Domain and Improved PHOX2B Missense Variant Interpretation by Utilization of In Silico Prediction Tools
Pathogenic heterozygous variants in PHOX2B are associated with congenital central hypoventilation syndrome (CCHS), which is characterized by autonomic nervous system dysregulation severely affecting respiratory control. The interpretation of PHOX2B missense variation is challenging due to their rarity and the lack of available functional evidence. Consequently, most PHOX2B missense variants are classified as variants of uncertain significance (VUSs), complicating the timely diagnosis and clinical management of the condition. To generate an improved model for assessments of PHOX2B missense variants, a methodology was derived to evaluate all PHOX2B missense variants in the literature and public/private databases according to a consensus classification framework and assigned pathogenicity classifications. Pathogenicity prediction scores from the in silico prediction tools CADD, REVEL, BayesDel, and AlphaMissense were obtained for all variants. A weighted logistic regression in a multiple imputation framework was performed to assess the strength of evidence supporting application of ACMG/AMP guidelines′ PP3/BP4 criteria. CADD, REVEL, and BayesDel meet the predictive strengths for PP3/BP4 recommended by the Clinical Genome Resource (ClinGen). Based on their areas under the curve and low proportions of variants with indeterminate pathogenicity predictions, BayesDel and REVEL were the strongest predictive tools and should be utilized for routine PHOX2B missense variant assessment with this study′s calculated score thresholds for PP3/BP4 strength levels. Furthermore, the positional distribution of pathogenic and benign variants was analyzed to assess potential hotspots or critical functional domains in PHOX2B , and pathogenic variants were found to cluster in the homeodomain. The enrichment of pathogenic variation was substantiated by the prediction tools, supporting the use of the PM1 criterion for variants in the homeodomain. This calibration of existing computational prediction tools for PHOX2B missense variant classification and recognition of the homeodomain variants will enable fewer VUS classifications in favor of conclusive results, aiding in these individuals′ care.
- Open Access
- 13 November 2025
- Published by Wiley
International Congenital Central Hypoventilation Syndrome (CCHS) Registry: Analysis of Patient-Reported Symptoms by PHOX2B Variant
Introduction. CCHS is a rare disorder caused by PHOX2B gene variants. While CCHS hallmarks are hypoventilation and respiratory control dysfunction necessitating lifelong artificial ventilatory support, affected individuals also experience widespread, but less studied, autonomic nervous system (ANS) dysregulation. PHOX2B variants may be divided into moderate and severe groups based upon molecular and in-silico data. The International CCHS Registry is a secure repository for longitudinal data from individuals with a PHOX2B variant-confirmed diagnosis, including information on seven systems served by the ANS (cardiovascular, gastrointestinal, neurological, ophthalmologic, renal/urinary, respiratory, sudomotor). Our objective was to analyze patient-reported symptoms (PRS) across all ANS-served systems and determine their relationship with PHOX2B variant severity. We hypothesized an increase in PRS in all organ systems in individuals with severe variants. Methods. This study focused on completed initial surveys. Descriptive statistics were generated for all PRS, and by variant groups, with statistical comparison using the Wilcoxon Rank-Sum and Fisher’s exact tests. Results. Analysis of 148 surveys confirmed broad, multi-system ANS dysfunction in CCHS. Those with severe PHOX2B variants were more likely to report cardiovascular, gastrointestinal, neurological, and ophthalmological system dysfunction compared to individuals with moderate variants. Individuals with severe PHOX2B variants reported significantly more symptoms in 6/7 organ systems than those with moderate variants. Conclusions. The individual-reported impact of CCHS varies by both PHOX2B variant severity and the ANS organ system/symptom manifestations. Beyond the traditional clinical focus on cardiorespiratory dysfunction, these results highlight other ANS-related systems that are critical for comprehensive clinical management and future therapeutic trial design.
- 13 November 2025
- Published by Wiley
Open AccessInternational Congenital Central Hypoventilation Syndrome (CCHS) Registry: Analysis of Patient-Reported Symptoms by PHOX2B Variant
Introduction. CCHS is a rare disorder caused by PHOX2B gene variants. While CCHS hallmarks are hypoventilation and respiratory control dysfunction necessitating lifelong artificial ventilatory support, affected individuals also experience widespread, but less studied, autonomic nervous system (ANS) dysregulation. PHOX2B variants may be divided into moderate and severe groups based upon molecular and in-silico data. The International CCHS Registry is a secure repository for longitudinal data from individuals with a PHOX2B variant-confirmed diagnosis, including information on seven systems served by the ANS (cardiovascular, gastrointestinal, neurological, ophthalmologic, renal/urinary, respiratory, sudomotor). Our objective was to analyze patient-reported symptoms (PRS) across all ANS-served systems and determine their relationship with PHOX2B variant severity. We hypothesized an increase in PRS in all organ systems in individuals with severe variants. Methods. This study focused on completed initial surveys. Descriptive statistics were generated for all PRS, and by variant groups, with statistical comparison using the Wilcoxon Rank-Sum and Fisher’s exact tests. Results. Analysis of 148 surveys confirmed broad, multi-system ANS dysfunction in CCHS. Those with severe PHOX2B variants were more likely to report cardiovascular, gastrointestinal, neurological, and ophthalmological system dysfunction compared to individuals with moderate variants. Individuals with severe PHOX2B variants reported significantly more symptoms in 6/7 organ systems than those with moderate variants. Conclusions. The individual-reported impact of CCHS varies by both PHOX2B variant severity and the ANS organ system/symptom manifestations. Beyond the traditional clinical focus on cardiorespiratory dysfunction, these results highlight other ANS-related systems that are critical for comprehensive clinical management and future therapeutic trial design.
- Open Access
- 28 March 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (4) , e71072
Reliability of Composite Autonomic Symptom Score (COMPASS)‐31 in Congenital Central Hypoventilation Syndrome
Rationale: Congenital central hypoventilation syndrome (CCHS) is a rare disorder characterized by alveolar hypoventilation and variable autonomic nervous system (ANS) dysfunction (ANSD) due to mutations in PHOX2B, a gene crucial for ANS neural crest lineage differentiation.Objectives and Methods: Our prospective study aims were twofold: to (1) assess the relationships between the subjective Composite Autonomic Symptom Score (COMPASS)‐31 and objective indices of ANSD obtained from heart rate variability analyses, ambulatory blood pressure (BP) monitoring, and CO2 chemosensitivities and (2) describe the organ system ANSD, its relationship to PHOX2B genotype, and its consequences on quality of life (PedsQL) in children with CCHS.Results: Thirty‐two PHOX2B mutation‐confirmed subjects (median [range] age 9.2 years (4.4; 18.0), 15 girls) were enrolled. COMPASS‐31 was assessed in 32 matched (sex and age, range: 4.3; 18.9 years) healthy controls. As compared to healthy controls, children with CCHS had increased vasomotor (p = 0.001), secretomotor (p = 0.021), gastrointestinal (p = 0.002) and pupillomotor (p = 0.028) scores and decreased orthostatic intolerance scores (p = 0.050). There was no difference in overall COMPASS‐31 score between CCHS and controls (p = 0.083). However, in CCHS, overall COMPASS‐31 scores correlated with high frequencies (HF) normalized (cardiac parasympathetic modulation: R = −0.53; p = 0.002), low frequencies (LF)/HF ratio (R = 0.56; p< 0.001), and both systolic and diastolic nighttime BP dipping (R = 0.45, p = 0.012 and R = 0.40, p = 0.028, respectively). No significant relationships between COMPASS‐31 scores and chemosensitivity testing, PedsQL scores, or PHOX2B genotype were identified.Conclusions: COMPASS‐31 identified some aspects of CCHS‐related ANSD, and scores correlate with objective ANS function measures, supporting the potential utility of COMPASS‐31 in CCHS.
- 28 March 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (4) , e71072
Open AccessReliability of Composite Autonomic Symptom Score (COMPASS)‐31 in Congenital Central Hypoventilation Syndrome
Rationale: Congenital central hypoventilation syndrome (CCHS) is a rare disorder characterized by alveolar hypoventilation and variable autonomic nervous system (ANS) dysfunction (ANSD) due to mutations in PHOX2B, a gene crucial for ANS neural crest lineage differentiation.Objectives and Methods: Our prospective study aims were twofold: to (1) assess the relationships between the subjective Composite Autonomic Symptom Score (COMPASS)‐31 and objective indices of ANSD obtained from heart rate variability analyses, ambulatory blood pressure (BP) monitoring, and CO2 chemosensitivities and (2) describe the organ system ANSD, its relationship to PHOX2B genotype, and its consequences on quality of life (PedsQL) in children with CCHS.Results: Thirty‐two PHOX2B mutation‐confirmed subjects (median [range] age 9.2 years (4.4; 18.0), 15 girls) were enrolled. COMPASS‐31 was assessed in 32 matched (sex and age, range: 4.3; 18.9 years) healthy controls. As compared to healthy controls, children with CCHS had increased vasomotor (p = 0.001), secretomotor (p = 0.021), gastrointestinal (p = 0.002) and pupillomotor (p = 0.028) scores and decreased orthostatic intolerance scores (p = 0.050). There was no difference in overall COMPASS‐31 score between CCHS and controls (p = 0.083). However, in CCHS, overall COMPASS‐31 scores correlated with high frequencies (HF) normalized (cardiac parasympathetic modulation: R = −0.53; p = 0.002), low frequencies (LF)/HF ratio (R = 0.56; p< 0.001), and both systolic and diastolic nighttime BP dipping (R = 0.45, p = 0.012 and R = 0.40, p = 0.028, respectively). No significant relationships between COMPASS‐31 scores and chemosensitivity testing, PedsQL scores, or PHOX2B genotype were identified.Conclusions: COMPASS‐31 identified some aspects of CCHS‐related ANSD, and scores correlate with objective ANS function measures, supporting the potential utility of COMPASS‐31 in CCHS.
- Open Access
- 21 March 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (3) , e71012
Congenital Central Hypoventilation Syndrome (CCHS): Patient Quality of Life and Caregiver Burden
Background: Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder characterized by autonomic dysregulation and abnormal control of breathing, necessitating lifelong artificial ventilation. The impact of CCHS on patient quality of life (QoL) and caregiver burden remains unquantified.Methods: A cross‐sectional study of QoL in CCHS patients (≥ 12 years; WHOQOL–BREF) and burden in CCHS caregivers (Zarit Burden Interview) was conducted. Participants were recruited from CCHS support organizations. Participant age group, sex, primary language, and country of residence were collected.Results: Two hundred seventy‐one individuals (78 CCHS, 193 caregivers) from 15 countries participated. CCHS patients reported significantly reduced physical, psychological, and social relationships domain scores compared to healthy controls (p < 0.01), yet > 70% reported good overall QoL. Over half reported moderate or worse impact on QoL items including medical treatment dependence and cognitive function. Young CCHS patients (< 25 years) reported better overall QoL and general health than those ≥ 25 years. CCHS caregiver burden was increased compared to that reported in other chronic diseases, with > 50% reporting frequent caregiving‐induced stress. Caregivers who reported financial issues also reported higher total burden (p < 0.05).Conclusions: CCHS QoL scores are depressed compared to healthy individuals. This study identified specific domains of QoL and caregiver burden most impacted by CCHS, revealed a relationship between age and QoL in CCHS, and finances and burden in caregivers. Results offer targets for future interventions to enhance QoL in CCHS and reduce caregiver burden. Further work is needed to elucidate the relationship between CCHS impact and disease‐ and treatment‐specific factors.
- 21 March 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (3) , e71012
Open AccessCongenital Central Hypoventilation Syndrome (CCHS): Patient Quality of Life and Caregiver Burden
Background: Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder characterized by autonomic dysregulation and abnormal control of breathing, necessitating lifelong artificial ventilation. The impact of CCHS on patient quality of life (QoL) and caregiver burden remains unquantified.Methods: A cross‐sectional study of QoL in CCHS patients (≥ 12 years; WHOQOL–BREF) and burden in CCHS caregivers (Zarit Burden Interview) was conducted. Participants were recruited from CCHS support organizations. Participant age group, sex, primary language, and country of residence were collected.Results: Two hundred seventy‐one individuals (78 CCHS, 193 caregivers) from 15 countries participated. CCHS patients reported significantly reduced physical, psychological, and social relationships domain scores compared to healthy controls (p < 0.01), yet > 70% reported good overall QoL. Over half reported moderate or worse impact on QoL items including medical treatment dependence and cognitive function. Young CCHS patients (< 25 years) reported better overall QoL and general health than those ≥ 25 years. CCHS caregiver burden was increased compared to that reported in other chronic diseases, with > 50% reporting frequent caregiving‐induced stress. Caregivers who reported financial issues also reported higher total burden (p < 0.05).Conclusions: CCHS QoL scores are depressed compared to healthy individuals. This study identified specific domains of QoL and caregiver burden most impacted by CCHS, revealed a relationship between age and QoL in CCHS, and finances and burden in caregivers. Results offer targets for future interventions to enhance QoL in CCHS and reduce caregiver burden. Further work is needed to elucidate the relationship between CCHS impact and disease‐ and treatment‐specific factors.
- Open Access
- 27 December 2024
- Published by Wiley
Congenital Central Hypoventilation Syndrome (CCHS): Patient Quality of Life and Caregiver Burden
Background: Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder characterized by autonomic dysregulation and abnormal control of breathing, necessitating lifelong artificial ventilation. The impact of CCHS on patient quality of life (QoL) and caregiver burden remains unquantified. Methods: A cross-sectional study of QoL in CCHS patients (≥12 years; WHOQOL–BREF) and burden in CCHS caregivers (Zarit Burden Interview) was conducted. Participants were recruited from CCHS support organizations. Participant age group, sex, primary language, and country of residence were collected. Results: 271 individuals (78 CCHS, 193 caregivers) from 15 countries participated. CCHS patients reported significantly reduced physical, psychological, and social relationships domain scores compared to healthy controls (p70% reported good overall QoL. Over half reported moderate or worse impact on QoL items including medical treatment dependence and cognitive function. Young CCHS patients (50% reporting frequent caregiving-induced stress. Caregivers who reported financial issues also reported higher total burden (pConclusions: CCHS QoL scores are depressed compared to healthy individuals. This study identified specific domains of QoL and caregiver burden most impacted by CCHS, revealed a relationship between age and QoL in CCHS, and finances and burden in caregivers. Results offer targets for future interventions to enhance QoL in CCHS and reduce caregiver burden. Further work is needed to elucidate the relationship between CCHS impact and disease- and treatment-specific factors.
- 27 December 2024
- Published by Wiley
Open AccessCongenital Central Hypoventilation Syndrome (CCHS): Patient Quality of Life and Caregiver Burden
Background: Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder characterized by autonomic dysregulation and abnormal control of breathing, necessitating lifelong artificial ventilation. The impact of CCHS on patient quality of life (QoL) and caregiver burden remains unquantified. Methods: A cross-sectional study of QoL in CCHS patients (≥12 years; WHOQOL–BREF) and burden in CCHS caregivers (Zarit Burden Interview) was conducted. Participants were recruited from CCHS support organizations. Participant age group, sex, primary language, and country of residence were collected. Results: 271 individuals (78 CCHS, 193 caregivers) from 15 countries participated. CCHS patients reported significantly reduced physical, psychological, and social relationships domain scores compared to healthy controls (p70% reported good overall QoL. Over half reported moderate or worse impact on QoL items including medical treatment dependence and cognitive function. Young CCHS patients (50% reporting frequent caregiving-induced stress. Caregivers who reported financial issues also reported higher total burden (pConclusions: CCHS QoL scores are depressed compared to healthy individuals. This study identified specific domains of QoL and caregiver burden most impacted by CCHS, revealed a relationship between age and QoL in CCHS, and finances and burden in caregivers. Results offer targets for future interventions to enhance QoL in CCHS and reduce caregiver burden. Further work is needed to elucidate the relationship between CCHS impact and disease- and treatment-specific factors.
- Open Access
- 20 July 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 1-9
ROHHAD and Prader-Willi syndrome (PWS): clinical and genetic comparison
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is a very rare and potentially fatal pediatric disorder, the cause of which is presently unknown. ROHHAD is often compared to Prader-Willi syndrome (PWS) because both share childhood obesity as one of their most prominent and recognizable signs, and because other symptoms such as hypoventilation and autonomic dysfunction are seen in both. These phenotypic similarities suggest they might be etiologically related conditions. We performed an in-depth clinical comparison of the phenotypes of ROHHAD and PWS and used NGS and Sanger sequencing to analyze the coding regions of genes in the PWS region among seven ROHHAD probands. Detailed clinical comparison of ROHHAD and PWS patients revealed many important differences between the phenotypes. In particular, we highlight the fact that the areas of apparent overlap (childhood-onset obesity, hypoventilation, autonomic dysfunction) actually differ in fundamental ways, including different forms and severity of hypoventilation, different rates of obesity onset, and different manifestations of autonomic dysfunction. We did not detect any disease-causing mutations within PWS candidate genes in ROHHAD probands. ROHHAD and PWS are clinically distinct conditions, and do not share a genetic etiology. Our detailed clinical comparison and genetic analyses should assist physicians in timely distinction between the two disorders in obese children. Of particular importance, ROHHAD patients will have had a normal and healthy first year of life; something that is never seen in infants with PWS.
- 20 July 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 1-9
Open AccessROHHAD and Prader-Willi syndrome (PWS): clinical and genetic comparison
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is a very rare and potentially fatal pediatric disorder, the cause of which is presently unknown. ROHHAD is often compared to Prader-Willi syndrome (PWS) because both share childhood obesity as one of their most prominent and recognizable signs, and because other symptoms such as hypoventilation and autonomic dysfunction are seen in both. These phenotypic similarities suggest they might be etiologically related conditions. We performed an in-depth clinical comparison of the phenotypes of ROHHAD and PWS and used NGS and Sanger sequencing to analyze the coding regions of genes in the PWS region among seven ROHHAD probands. Detailed clinical comparison of ROHHAD and PWS patients revealed many important differences between the phenotypes. In particular, we highlight the fact that the areas of apparent overlap (childhood-onset obesity, hypoventilation, autonomic dysfunction) actually differ in fundamental ways, including different forms and severity of hypoventilation, different rates of obesity onset, and different manifestations of autonomic dysfunction. We did not detect any disease-causing mutations within PWS candidate genes in ROHHAD probands. ROHHAD and PWS are clinically distinct conditions, and do not share a genetic etiology. Our detailed clinical comparison and genetic analyses should assist physicians in timely distinction between the two disorders in obese children. Of particular importance, ROHHAD patients will have had a normal and healthy first year of life; something that is never seen in infants with PWS.
- 1 January 2016
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 221, 59-63
Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD
- 1 January 2016
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 221, 59-63
Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD
- Open Access
- 25 August 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-13
Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of trios, monozygotic twins and tumours
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) is thought to be a genetic disease caused by de novo mutations, though causative mutations have yet to be identified. We searched for de novo coding mutations among a carefully-diagnosed and clinically homogeneous cohort of 35 ROHHAD patients. We sequenced the exomes of seven ROHHAD trios, plus tumours from four of these patients and the unaffected monozygotic (MZ) twin of one (discovery cohort), to identify constitutional and somatic de novo sequence variants. We further analyzed this exome data to search for candidate genes under autosomal dominant and recessive models, and to identify structural variations. Candidate genes were tested by exome or Sanger sequencing in a replication cohort of 28 ROHHAD singletons. The analysis of the trio-based exomes found 13 de novo variants. However, no two patients had de novo variants in the same gene, and additional patient exomes and mutation analysis in the replication cohort did not provide strong genetic evidence to implicate any of these sequence variants in ROHHAD. Somatic comparisons revealed no coding differences between any blood and tumour samples, or between the two discordant MZ twins. Neither autosomal dominant nor recessive analysis yielded candidate genes for ROHHAD, and we did not identify any potentially causative structural variations. Clinical exome sequencing is highly unlikely to be a useful diagnostic test in patients with true ROHHAD. As ROHHAD has a high risk for fatality if not properly managed, it remains imperative to expand the search for non-exomic genetic risk factors, as well as to investigate other possible mechanisms of disease. In so doing, we will be able to confirm objectively the ROHHAD diagnosis and to contribute to our understanding of obesity, respiratory control, hypothalamic function, and autonomic regulation.
- 25 August 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-13
Open AccessRapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of trios, monozygotic twins and tumours
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) is thought to be a genetic disease caused by de novo mutations, though causative mutations have yet to be identified. We searched for de novo coding mutations among a carefully-diagnosed and clinically homogeneous cohort of 35 ROHHAD patients. We sequenced the exomes of seven ROHHAD trios, plus tumours from four of these patients and the unaffected monozygotic (MZ) twin of one (discovery cohort), to identify constitutional and somatic de novo sequence variants. We further analyzed this exome data to search for candidate genes under autosomal dominant and recessive models, and to identify structural variations. Candidate genes were tested by exome or Sanger sequencing in a replication cohort of 28 ROHHAD singletons. The analysis of the trio-based exomes found 13 de novo variants. However, no two patients had de novo variants in the same gene, and additional patient exomes and mutation analysis in the replication cohort did not provide strong genetic evidence to implicate any of these sequence variants in ROHHAD. Somatic comparisons revealed no coding differences between any blood and tumour samples, or between the two discordant MZ twins. Neither autosomal dominant nor recessive analysis yielded candidate genes for ROHHAD, and we did not identify any potentially causative structural variations. Clinical exome sequencing is highly unlikely to be a useful diagnostic test in patients with true ROHHAD. As ROHHAD has a high risk for fatality if not properly managed, it remains imperative to expand the search for non-exomic genetic risk factors, as well as to investigate other possible mechanisms of disease. In so doing, we will be able to confirm objectively the ROHHAD diagnosis and to contribute to our understanding of obesity, respiratory control, hypothalamic function, and autonomic regulation.